Home›Trial›NCT07038200
🔬NCT07038200Phase 3RECRUITING

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

Study Summary

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

Conditions
Facioscapulohumeral Muscular DystrophyFSHDFSHD - Facioscapulohumeral Muscular DystrophyFSHD1FSHD2Fascioscapulohumeral Muscular DystrophyFascioscapulohumeral Muscular Dystrophy Type 1Fascioscapulohumeral Muscular Dystrophy Type 2Facioscapulohumeral Muscular Dystrophy 1Facioscapulohumeral DystrophyFacio-Scapulo-Humeral DystrophyFacioscapulohumeral Muscular Dystrophy 2Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1)FSH Muscular DystrophyLandouzy Dejerine DystrophyLandouzy-Dejerine Muscular DystrophyLandouzy-Dejerine Syndrome
Interventions / Drugs
AOC-1020Placebo
View on ClinicalTrials.gov ↗
Sponsor
RNA
Avidity Biosciences
RNA Therapeutics
D48/100
Study Details
Enrollment200 participants
Primary Completion—
Lead SponsorAvidity Biosciences, Inc.
Data Retrieved2026-04-11 04:26:08.607692+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.